A new consensus report addressing the benefits, challenges, and recommendations related to automated insulin delivery (AID) is being jointly published today by two leading diabetes organizations: the American Diabetes Association^® (ADA) and the European Association for the Study of Diabetes (EASD). The ADA and the EASD convened a joint Diabetes Technology Working Group to review the current landscape of AID systems and recommend targeted actions.

“The report addresses the clinical usage of AID systems from a practical point of view rather than as  a meta-analysis or a review of all relevant clinical studies,” explains lead author Jennifer Sherr, MD, PhD, professor of pediatrics, Pediatric Endocrinology, Yale University. “As such, the benefits and limitations of systems are discussed while also considering safety, regulatory pathways, and access to this technology.”

The report is geared toward diabetologists and other specialists, as well as diabetes nurses and specialist dieticians. Colleagues working in regulatory agencies, health care organizations, and related media may also benefit from this consensus report. “We are excited to share this report to guide health care professionals globally on these technological advances for people with diabetes,” added Robert Gabbay, MD, PhD chief scientific and medical officer of the ADA.

“Most other publications about AID systems are sponsored by the manufacturers of the systems. Our report is independent and endorsed by the ADA and the EASD,” added Mark Evans, MD, FRCP, professor of diabetic medicine, University of Cambridge, UK “Many clinically relevant aspects, including safety, are addressed in this report. The aim of this report is to encourage ongoing improvement of this technology, its safe and effective use, and its accessibility to all who can benefit from it.”

Read the full consensus report available from Diabetes Care^® ahead of the final print and online issue.